National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Access to Care (1)
- Adverse Drug Events (ADE) (1)
- Alcohol Use (1)
- Behavioral Health (3)
- Cancer (1)
- Cardiovascular Conditions (1)
- Children/Adolescents (1)
- Chronic Conditions (5)
- Clinical Decision Support (CDS) (1)
- Clinician-Patient Communication (3)
- Communication (1)
- Comparative Effectiveness (2)
- COVID-19 (1)
- Depression (2)
- Diabetes (1)
- Diagnostic Safety and Quality (1)
- Disparities (1)
- Education: Academic (1)
- Education: Patient and Caregiver (2)
- Elderly (1)
- Electronic Health Records (EHRs) (1)
- Evidence-Based Practice (3)
- Guidelines (1)
- Healthcare Cost and Utilization Project (HCUP) (2)
- Healthcare Costs (3)
- Healthcare Delivery (2)
- Health Information Exchange (HIE) (1)
- Health Information Technology (HIT) (1)
- Health Insurance (3)
- Heart Disease and Health (1)
- Hepatitis (1)
- Hospitalization (2)
- Hospital Readmissions (1)
- (-) Human Immunodeficiency Virus (HIV) (48)
- Infectious Diseases (2)
- Injuries and Wounds (1)
- Lifestyle Changes (1)
- Low-Income (1)
- Medicaid (5)
- Medicare (2)
- Medication (12)
- Men's Health (2)
- Mortality (2)
- Nutrition (1)
- Obesity: Weight Management (1)
- Opioids (3)
- Outcomes (4)
- Pain (1)
- Palliative Care (1)
- Patient-Centered Healthcare (1)
- Patient-Centered Outcomes Research (2)
- Patient Adherence/Compliance (3)
- Patient and Family Engagement (1)
- Patient Experience (1)
- Policy (2)
- Practice Patterns (1)
- Prevention (6)
- Provider (1)
- Public Health (2)
- Quality of Life (1)
- Racial and Ethnic Minorities (8)
- Respiratory Conditions (2)
- Risk (6)
- Screening (3)
- Sex Factors (1)
- Sexual Health (1)
- Social Determinants of Health (1)
- Social Stigma (4)
- Substance Abuse (6)
- Tobacco Use (1)
- Treatments (1)
- Urban Health (3)
- Vulnerable Populations (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 25 of 48 Research Studies DisplayedCoburn SB, Lang R, Zhang J
Statins utilization in adults with HIV: the treatment gap and predictors of statin initiation.
The purpose of this study was to describe trends in statin eligibility and subsequent statin initiation among people with HIV (PWH) from and identify the predictors of statin initiation. The researchers collected data from 12 United States cohorts between 2001 and 2017. The study found that among 16,409 PWH, 45% met statin eligibility criteria per guidelines for the time period from 2001 to 2017. Statin eligibility ranged from 22% to 25% from 2001 to 2013, and initiation increased from 13% to 45%. In 2014, 51% were statin-eligible, among whom 25% initiated statins, which increased to 32% by 2017. The researchers concluded that there is a substantial statin treatment gap, expanded by the 2013 ACC/AHA guidelines.
AHRQ-funded; 90047713.
Citation: Coburn SB, Lang R, Zhang J .
Statins utilization in adults with HIV: the treatment gap and predictors of statin initiation.
J Acquir Immune Defic Syndr 2022 Dec 15;91(5):469-78. doi: 10.1097/qai.0000000000003083..
Keywords: Medication, Human Immunodeficiency Virus (HIV), Access to Care, Practice Patterns, Cardiovascular Conditions
Rich KM, Zubiago J, Murphy M
The association of gender with receptive and distributive needle sharing among individuals who inject drugs.
The authors sought to assess the relationship between gender and needle sharing with injection drug use. Using data from the 2010-2019 National Survey on Drug Use and Health (NSDUH) datasets, they found that women were more likely in comparison with men to share needles both through receptive and distributive means. They concluded that expansion of interventions, including syringe service programs, to increase access to sterile injection equipment, is of great importance.
AHRQ-funded; HS026008.
Citation: Rich KM, Zubiago J, Murphy M .
The association of gender with receptive and distributive needle sharing among individuals who inject drugs.
Harm Reduct J 2022 Sep 30;19(1):108. doi: 10.1186/s12954-022-00689-3..
Keywords: Human Immunodeficiency Virus (HIV), Substance Abuse, Behavioral Health, Sex Factors
Edwards JK, Cole SR, Breger TL
Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population.
This study examined 5-year mortality for adults entering human immunodeficiency virus (HIV) care under universal early treatment compared with the general US population. A total of 82,766 adults entering HIV treatment at North American AIDS Cohort Collaboration clinical sites in the United States were used to compute mortality over 5 years. The authors used NCHS data to construct a cohort representing a subset of the US population matched to study participants on key characteristics. For the study period of 1999 to 2017, the 5-year mortality among adults with HIV was 7.9% higher than expected based on the US general population. Under universal early treatment, the elevation in mortality for people with HIV would have been 7.2%. During the most recent calendar period examined (2011-2017) the elevation in mortality for people with HIV was 2.6% under observed treatment patterns and 2.1% under universal early treatment.
AHRQ-funded; 90047713.
Citation: Edwards JK, Cole SR, Breger TL .
Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population.
Clin Infect Dis 2022 Sep 14;75(5):867-74. doi: 10.1093/cid/ciab1030..
Keywords: Human Immunodeficiency Virus (HIV), Mortality, Outcomes
McGinnis KA, Justice AC, Moore RD
Discrimination and calibration of the veterans aging cohort study index 2.0 for predicting mortality among people with human immunodeficiency virus in North America.
Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), the authors translated Veterans Aging Cohort Study (VACS) Index 2.0 scores into validated probability estimates of mortality among people with HIV (PWH). They found that predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups. Based on this validation, they concluded that VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America.
AHRQ-funded; 90047713.
Citation: McGinnis KA, Justice AC, Moore RD .
Discrimination and calibration of the veterans aging cohort study index 2.0 for predicting mortality among people with human immunodeficiency virus in North America.
Clin Infect Dis 2022 Aug 25;75(2):297-304. doi: 10.1093/cid/ciab883..
Keywords: Human Immunodeficiency Virus (HIV), Chronic Conditions
Korthuis PT, Cook RR, Lum PJ
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Opioid Use Disorder (OUD) treatment medications can improve outcomes for human immunodeficiency virus (HIV) and also reduce opioid use. The purpose of the study was to determine if outpatient naltrexone treatment could also reduce opioid use and improve outcomes for HIV. The researchers reported that enrollment was stopped early because of slower than expected recruitment, resulting in 114 final participants with untreated OUD and HIV, with 62% positive for fentanyl, 60% positive for cocaine, and 47% positive for other opioids at the baseline. The intervention compared treatment as usual (TAU) of methadone or buprenorphine with extended-release naltrexone (XR-NTX) on group differences in viral suppression at 24 weeks and past 30-day use of opioids at 24 weeks. The study reported that at 24 weeks the outcome of viral suppression was similar for TAU and XR-NTX, and that fewer XR-NTX participants initiated medication than TAU participants. The outcome of previous 30-day use of opioids was similar for TAU as compared to XR-NTX. Of those participants who did initiate medication, those administered XR-NTX experienced less days of opioid use when compared with TAU in the prior 30 days. The researchers reported that the study evidence was not conclusive but did support that XR-NTX is not inferior to TAU for HIV viral suppression, and that study participants who started XR-NTX used less opioids at 24 weeks than participants who were administered TAU.
AHRQ-funded; HS026370.
Citation: Korthuis PT, Cook RR, Lum PJ .
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Addiction 2022 Jul;117(7):1961-71. doi: 10.1111/add.15836..
Keywords: Human Immunodeficiency Virus (HIV), Opioids, Substance Abuse, Behavioral Health, Medication, Treatments, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice
Cedillo G, George MC, Deshpande R
Toward safer opioid prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial.
Healthcare and behavioral health providers are lacking a methodology to implement the 2016 U.S. Centers for Disease Control and Prevention Opioid Prescribing Guideline (CDC Guideline), measure prescriber adherence to it, and systematically test its effect on patient and public health outcomes. The Guideline is currently being reviewed and revised due to concern that it may be harmful to people with chronic pain on long-term opioid therapy (CP-LTOT). The purpose of the study was to develop and test a CDC Guideline implementation strategy termed “TOWER,” focused on an outpatient HIV primary care setting with patients with CP-LTOT. The TOWER strategy included: 1) a patient-facing app for opioid management (OM-App); 2) a template for progress notes (OM-Note) intended to guide the patient’s office visit; and 3) a primary care provider (PCP) training. TOWER was developed in a multi-step, stakeholder-engaged process within a behavioral change framework. The researchers evaluated the TOWER strategy in a randomized-controlled trial of HIV-PCPs (N=11) and their patients with HIV and CP-LTOT (N=40). The main outcome was CDC Guideline adherence based on electronic health record (EHR) documentation and measured by the Safer Opioid Prescribing Tool (SOPTET). Qualitative data was also collected, including one-on-one PCP interviews. The study found that the PCPs randomized to utilize the TOWER strategy were 48% more CDC Guideline adherent. Qualitative data reflected high levels of intervention provider confidence in administering the TOWER processes, and that the OM-Note supported provider efforts, but experience with the patient-facing OM-App was mixed. The study concluded that adherence to the 2016 CDC Guidelines is not associated with worsening of outcomes for people with HIV with CP-LTOT, and adherence to the CDC Guidelines can be promoted and measured. The researchers recommend additional research into the scalability of these results and the impact of CDC Guideline adherence on public health.
AHRQ-funded; HS025641.
Citation: Cedillo G, George MC, Deshpande R .
Toward safer opioid prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial.
Addict Sci Clin Pract 2022 May 16;17(1):28. doi: 10.1186/s13722-022-00311-8..
Keywords: Opioids, Medication, Human Immunodeficiency Virus (HIV), Guidelines, Evidence-Based Practice
Kim HN, Nance RM, Lo Re V
Development and validation of a model for prediction of end-stage liver disease in people with HIV.
The authors developed and validated a risk-prediction model for end-stage liver disease (ESLD) among people with HIV (PWH). They developed and validated a risk prediction model for ESLD among PWH who received care in 12 cohorts of the North American AIDS Cohort Collaboration on Research and Design and found that their model of readily accessible clinical parameters predicted ESLD in a large diverse population of PWH.
AHRQ-funded; 90047713.
Citation: Kim HN, Nance RM, Lo Re V .
Development and validation of a model for prediction of end-stage liver disease in people with HIV.
J Acquir Immune Defic Syndr 2022 Apr;89(4):396-404. doi: 10.1097/qai.0000000000002886..
Keywords: Chronic Conditions, Human Immunodeficiency Virus (HIV), Risk
Koh MJ, Merrill MH, Koh MJ
Comparative outcomes for mature T and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Citation: Koh MJ, Merrill MH, Koh MJ .
Comparative outcomes for mature T and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Blood Adv 2022 Mar 8;6(5):1420-31. doi: 10.1182/bloodadvances.2021006208.
AHRQ-funded; 90051652..
AHRQ-funded; 90051652..
Keywords: Human Immunodeficiency Virus (HIV), Comparative Effectiveness, Outcomes, Evidence-Based Practice
Van Gerwen OT, Talluri R, Camino AF
Human immunodeficiency virus/sexually transmitted infection testing preferences for young Black men who have sex with men in the Southeastern United States: implications for a post-COVID-19 era.
Study researchers used a discrete choice experiment to assess the preferences of Young Black Men Who Have Sex with Men (YBMSM) in the Southeastern U.S. regarding their preferences for human immunodeficiency virus (HIV)/ sexually transmitted infection (STI) testing locations, staffing, cost, and hours of operation. Between June 2018 and December 2019, 213 YBMSM between the ages of 16-35 years, located in Birmingham, Alabama and Jackson, Mississippi completed online surveys evaluating their preferences. Traditional, stationary testing locations were preferred by both groups over mobile testing vans. The most significant difference in preference was for local health departments in Alabama, and STI testing-only clinics in Mississippi. Both groups preferred clinician-performed testing over technician-performed testing or self-testing, with additional preferences for free testing and phone results notification (versus text). The most preferred combination among all participants was the $5 clinician-performed testing at the health department. The study concluded that YBMSM in the Southeastern United States prefer traditional testing locations staffed by experienced personnel. The study researchers advise that more research is needed to inform the best ways to approach HIV/STI testing services for YBMSM, especially in the post-COVID-19 era when delivery models are shifting toward health-focused strategies which are home-based and remote.
AHRQ-funded; HS013852.
Citation: Van Gerwen OT, Talluri R, Camino AF .
Human immunodeficiency virus/sexually transmitted infection testing preferences for young Black men who have sex with men in the Southeastern United States: implications for a post-COVID-19 era.
Sex Transm Dis 2022 Mar;49(3):208-15. doi: 10.1097/olq.0000000000001559..
Keywords: COVID-19, Human Immunodeficiency Virus (HIV), Infectious Diseases, Racial and Ethnic Minorities, Men's Health
Wyse JJ, McGinnis KA, Edelman EJ
Twelve-month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV.
Although opioid agonist therapy (OAT) is associated with positive health outcomes, including improved HIV management, long-term retention in OAT remains low among patients with opioid use disorder (OUD). The investigators concluded that history of homelessness was associated with a lower likelihood of retention. Predictors of retention were largely distinct between patients with HIV and patients without HIV. Findings highlighted the need for clinical, systems, and research initiatives to better understand and improve OAT retention.
AHRQ-funded; HS026370.
Citation: Wyse JJ, McGinnis KA, Edelman EJ .
Twelve-month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV.
AIDS Behav 2022 Mar;26(3):975-85. doi: 10.1007/s10461-021-03452-0..
Keywords: Opioids, Substance Abuse, Behavioral Health, Human Immunodeficiency Virus (HIV)
Higashi RT, Rodriguez SA, Betts AC
Anal cancer screening among women with HIV: provider experiences and system-level challenges.
This article described current practices and barriers met in conducting anal cancer screenings for women living with HIV (WLWH) in an urban integrated safety-net system and in a non-profit community-based HIV clinic. Semi-structured interviews with clinical and administrative stakeholders were conducted to assess their screening for anal cancer experiences, knowledge, clinic practices and procedures. Barriers included limited knowledge of guidelines by providers and system-level issues such as lack of coordination between clinics and limitations on available resources. The authors concluded that screenings and follow-up require organization and coordination between multiple care teams, as well as improved clinical information systems to facilitate communication and infrastructure for managing abnormal results.
AHRQ-funded; HS022418.
Citation: Higashi RT, Rodriguez SA, Betts AC .
Anal cancer screening among women with HIV: provider experiences and system-level challenges.
AIDS Care 2022 Feb; 34(2):220-26. doi: 10.1080/09540121.2021.1883512..
Keywords: Cancer, Human Immunodeficiency Virus (HIV), Women, Screening
Van Gerwen OT, Austin EL, Camino AF
"It's behaviors, not identity": attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United States.
Investigators aimed to explore beliefs associated with HIV Pre-Exposure Prophylaxis (PrEP) among transgender women (TGW) in the Southeastern U.S., framed by the Health Belief Model. They identified several themes: frustration with conflation of transgender identity and HIV risk, inappropriate transgender representation in PrEP advertising, concerns for interactions between PrEP and hormone therapy, perception that PrEP is meant for cisgender men who have sex with men, and limited trans-affirming healthcare. Given the diversity of this population, they recommended nuanced messaging to educate and engage TGW in HIV prevention strategies, including PrEP.
AHRQ-funded; HS013852.
Citation: Van Gerwen OT, Austin EL, Camino AF .
"It's behaviors, not identity": attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United States.
PLoS One 2022 Jan 27;17(1):e0262205. doi: 10.1371/journal.pone.0262205..
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Sexual Health
Hobson JM, Gilstrap SR, Owens MA
Intersectional HIV and chronic pain stigma: implications for mood, sleep, and pain severity.
This study discusses chronic pain stigma in persons with HIV (PWH) and the consequences for mental and physical health which can lead to poor chronic pain outcome. This cross-sectional study enrolled 91 PWH and chronic pain patients, with six participants disqualified. Participants provided blood to determine CD 4+ count and viral load. They also completed standardized self-report questionnaires that assessed their experiences of HIV and chronic pain stigma, as well as depressive symptoms, experiences of insomnia, and pain severity. Measures used in the questionnaires included the HIV Stigma Mechanisms Scale, the Internalized Stigma of Chronic Pain scale, the Center for Epidemiologic Studies Depression (CED-S) Scale, the Insomnia Severity Index (ISI), and the Brief Pain Inventory Short-Form (BFI-SF). Participants were also questioned on opioid use. Results showed that for intersectional HIV and chronic pain stigma, 38% of participants were categorized as “high”, 28% were categorized as “moderate”, and 34% were categorized as “low”.
AHRQ-funded; HS013852.
Citation: Hobson JM, Gilstrap SR, Owens MA .
Intersectional HIV and chronic pain stigma: implications for mood, sleep, and pain severity.
J Int Assoc Provid AIDS Care 2022 Jan-Dec;21:23259582221077941. doi: 10.1177/23259582221077941..
Keywords: Human Immunodeficiency Virus (HIV), Pain, Chronic Conditions, Social Stigma, Depression
Nikolopoulos GK, Pavlitina E, Muth SQ
A network intervention that locates and intervenes with recently HIV-infected persons: the Transmission Reduction Intervention Project (TRIP).
The Transmission Reduction Intervention Project (TRIP) evaluated a network intervention to detect individuals infected with HIV within the past 6 months. Results indicated that strategic network tracing that starts with recently infected persons could support public health efforts to find and treat people early in their HIV infection.
AHRQ-funded; HS000084.
Citation: Nikolopoulos GK, Pavlitina E, Muth SQ .
A network intervention that locates and intervenes with recently HIV-infected persons: the Transmission Reduction Intervention Project (TRIP).
Sci Rep 2016 Dec 5;6:38100. doi: 10.1038/srep38100.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Public Health
Salinas JL, Rentsch C, Marconi VC
Baseline, time-updated, and cumulative HIV care metrics for predicting acute myocardial infarction and all-cause mortality.
The researchers studied prediction rates of myocardial infarction in those with HIV. They found that the Veterans Aging Cohort Study (VACS) Index provided better acute myocardial infarction and mortality prediction than CD4 count and HIV-1 RNA, concluding that current health determines risk more accurately than prior history.
AHRQ-funded; HS018372.
Citation: Salinas JL, Rentsch C, Marconi VC .
Baseline, time-updated, and cumulative HIV care metrics for predicting acute myocardial infarction and all-cause mortality.
Clin Infect Dis 2016 Dec 1;63(11):1423-30. doi: 10.1093/cid/ciw564.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Mortality, Heart Disease and Health, Risk
Merlin JS, Bulls HW, Vucovich LA
Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: a systematic review.
The authors conducted a systematic review to identify clinical trials and observational studies examining the impact of pharmacologic or non-pharmacologic interventions on pain and/or functional outcomes among HIV-infected individuals with chronic pain in high-development countries. They found that the only included controlled studies with positive results were of capsaicin and cannabis. Among the seven studies of pharmacologic interventions, the authors determined that five had substantial pharmaceutical industry sponsorship. Their findings highlight several important gaps in the HIV/chronic pain literature requiring further research.
AHRQ-funded; HS019465.
Citation: Merlin JS, Bulls HW, Vucovich LA .
Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: a systematic review.
AIDS Care 2016 Dec;28(12):1506-15. doi: 10.1080/09540121.2016.1191612.
.
.
Keywords: Chronic Conditions, Comparative Effectiveness, Human Immunodeficiency Virus (HIV), Medication, Patient-Centered Outcomes Research
Gaines TL, Caldwell JT, Ford CL
Relationship between a Centers for Disease Control and Prevention expanded HIV testing initiative and past-year testing by race/ethnicity: a multilevel analysis of the Behavioral Risk Factor Surveillance System.
The Centers for Disease Control and Prevention's (CDC) expanded testing initiative (ETI) aims to bolster HIV testing among populations disproportionately affected by the HIV epidemic by providing additional funding to health departments serving these communities. Controlling for individual- and state-level characteristics, ETI participation was independently and positively associated with past-year testing, but this association varied by race/ethnicity.
AHRQ-funded; HS022811.
Citation: Gaines TL, Caldwell JT, Ford CL .
Relationship between a Centers for Disease Control and Prevention expanded HIV testing initiative and past-year testing by race/ethnicity: a multilevel analysis of the Behavioral Risk Factor Surveillance System.
AIDS Care 2016;28(5):554-60. doi: 10.1080/09540121.2015.1131968.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Screening, Prevention, Racial and Ethnic Minorities
Earnshaw VA, Rosenthal L, Lang SM
Stigma, activism, and well-being among people living with HIV.
The researchers examined associations between experiences of HIV stigma and HIV activism, and test whether HIV activists benefit from greater well-being than non-activists. Their results suggest that HIV activists reported greater social network integration, greater social well-being, greater engagement in active coping with discrimination, and greater meaning in life than non-activists.
AHRQ-funded; HS022986.
Citation: Earnshaw VA, Rosenthal L, Lang SM .
Stigma, activism, and well-being among people living with HIV.
AIDS Care 2016;28(6):717-21. doi: 10.1080/09540121.2015.1124978.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Quality of Life, Depression, Social Determinants of Health, Social Stigma
Haines CF, Fleishman JA, Yehia BR
AHRQ Author: Fleishman JA
Closing the gap in antiretroviral initiation and viral suppression: time trends and racial disparities.
In the current antiretroviral (ART) era, the evolution of HIV guidelines and emergence of new ART agents might be expected to impact the times to ART initiation (AI) and HIV virologic suppression. The researchers sought to determine if times to AI and virologic suppression decreased and if disparities exist. Since 2007, times from enrollment to AI and virologic suppression have decreased significantly compared with 2003-2004.
AHRQ-authored.
Citation: Haines CF, Fleishman JA, Yehia BR .
Closing the gap in antiretroviral initiation and viral suppression: time trends and racial disparities.
J Acquir Immune Defic Syndr 2016 Nov 1;73(3):340-47. doi: 10.1097/qai.0000000000001114.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Disparities, Racial and Ethnic Minorities
Morgan E, Khanna AS, Skaathun B
Marijuana use among young black men who have sex with men and the HIV care continuum: findings from the uConnect cohort.
The authors investigated how substances most commonly used by young black men who have sex with men (YBMSM), such as marijuana, are related to the HIV continuum. They found that YBMSM who used marijuana heavily were more likely to be HIV-positive unaware than those who never used marijuana..
AHRQ-funded; HS000084.
Citation: Morgan E, Khanna AS, Skaathun B .
Marijuana use among young black men who have sex with men and the HIV care continuum: findings from the uConnect cohort.
Subst Use Misuse 2016 Nov 9;51(13):1751-9. doi: 10.1080/10826084.2016.1197265.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Racial and Ethnic Minorities, Racial and Ethnic Minorities, Substance Abuse
Ramos SR, Gordon P, Bakken S
Sociotechnical analysis of health information exchange consent processes in an HIV clinic.
The purpose of this study was to describe sociotechnical factors that influence health information exchange (HIE) consent for persons living with HIV (PLWH) at one clinic in New York City. The authors' approach revealed multiple interruptions in clinical workflow, staff and providers' time constraints, and lack of dedicated personnel focused on HIE consent as the major barriers to HIE consent, and they recommended having a dedicated person for facilitating HIE consent.
AHRQ-funded; HS023963.
Citation: Ramos SR, Gordon P, Bakken S .
Sociotechnical analysis of health information exchange consent processes in an HIV clinic.
J Assoc Nurses AIDS Care 2016 Nov - Dec;27(6):792-803. doi: 10.1016/j.jana.2016.08.001.
.
.
Keywords: Electronic Health Records (EHRs), Health Information Exchange (HIE), Health Information Technology (HIT), Human Immunodeficiency Virus (HIV)
Tiruneh YM, Wilson IB
What time is it? Adherence to antiretroviral therapy in Ethiopia.
This study assessed adherence to antiretroviral therapy (ART) among people living with HIV/AIDS in Ethiopia and explored the sociocultural context in which they relate to their regimen requirements. Its findings indicate that study participants are highly adherent to dose but less adherent to dose schedule. Strict dose time instructions were reported as stressful and unrealistic.
AHRQ-funded; HS000011.
Citation: Tiruneh YM, Wilson IB .
What time is it? Adherence to antiretroviral therapy in Ethiopia.
AIDS Behav 2016 Nov;20(11):2662-73. doi: 10.1007/s10461-016-1322-0.
.
.
Keywords: Patient Adherence/Compliance, Human Immunodeficiency Virus (HIV), Medication
Herrin M, Tate JP, Akgun KM
Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals.
The authors used data from the Veterans Aging Cohort Study to determine whether weight gain after antiretroviral therapy has a similar association with incident type 2 diabetes mellitus as weight gained among HIV-uninfected individuals. They found that weight gained during the first year after antiretroviral therapy initiation is associated with greater risk of diabetes mellitus than that among uninfected individuals.
AHRQ-funded; HS018372.
Citation: Herrin M, Tate JP, Akgun KM .
Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals.
J Acquir Immune Defic Syndr 2016 Oct 1;73(2):228-36. doi: 10.1097/qai.0000000000001071.
.
.
Keywords: Diabetes, Human Immunodeficiency Virus (HIV), Medication, Obesity: Weight Management
Eaton EF, Tamhane A, Saag M
Cost considerations in the current antiretroviral era.
The authors analyzed the relative cost-effectiveness of contemporary antiretroviral therapy in real-world clinical settings. They found that, among the participants studied, raltegravir and efavirenz-based regimens were the most cost-effective options for treatment-naive patients. They suggested that these findings are relevant given changes in recommended regimens for treatment-naive persons. The authors recommended that further data on the comparative effectiveness of efavirenz and rilpivirine are needed.
AHRQ-funded; HS013852.
Citation: Eaton EF, Tamhane A, Saag M .
Cost considerations in the current antiretroviral era.
AIDS 2016 Sep 10;30(14):2115-9. doi: 10.1097/qad.0000000000001120.
.
.
Keywords: Healthcare Costs, Human Immunodeficiency Virus (HIV), Medication
McManus KA, Rodney RC, Rhodes A
Affordable Care Act qualified health plan enrollment for AIDS Drug Assistance Program clients: Virginia's experience and best practices.
This article highlighted the benefits of the Affordable Care Act (ACA) for persons living with HIV and described the range of strategies employed by states to enroll patients in Qualified Health Plans (QHPs). It used the Virginia AIDS Drug Assistance Program ACA implementation to illustrate one program's shift to purchasing QHPs. The authors provided practical details of Virginia's implementation as well as insights and best practices at both the state and clinic level.
AHRQ-funded; HS024196.
Citation: McManus KA, Rodney RC, Rhodes A .
Affordable Care Act qualified health plan enrollment for AIDS Drug Assistance Program clients: Virginia's experience and best practices.
AIDS Res Hum Retroviruses 2016 Sep;32(9):885-91. doi: 10.1089/aid.2016.0033.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Medication, Policy